Diagnostics and therapy of sudden hearing loss.

Stefan K Plontke
{"title":"Diagnostics and therapy of sudden hearing loss.","authors":"Stefan K Plontke","doi":"10.3205/cto000144","DOIUrl":null,"url":null,"abstract":"<p><p>This article reviews recent aspects of diagnostics, differential diagnostics, and evidence in systemic and local therapy of idiopathic sudden sensorineural hearing loss (ISSHL). Since a number of disorders can be accompanied by sudden hearing loss, a meaningful and targeted diagnostic strategy is of utmost importance. An important differential diagnosis of sudden hearing loss are intralabyrinthine schwannomas (ILS). The incidence of ILS is probably significantly underestimated. This may be due to the lack of awareness or lack of explicit search for an intralabyrinthine tumor on MRI or an inappropriate MRI technique for the evaluation of sudden hearing loss (\"head MRI\" instead of \"temporal bone MRI\" with too high slice thicknesses). Therefore, the request to the radiologist should specifically include the question for (or exclusion of) an ILS. With special MRI techniques, it is possibly today to visualize an endolymphatic hydrops. The evidence in the therapy of ISSHL is - with respect to the quality and not quantity of studies - unsatisfying. The value of systemically (low dose) or intratympanically applied corticosteroids in the primary treatment of ISSHL is still unclear. In order to investigate the efficacy and safety of high dose corticosteroids as primary therapy for ISSHL, a national, multicenter, three-armed, randomized, triple-blind controlled clinical trial is currently performed in Germany (http://hodokort-studie.hno.org/). After insufficient recovery of the threshold with systemic therapy of ISSHL, intratympanic corticosteroid therapy appears to be associated with a significantly higher chance of an improved hearing threshold than no therapy or placebo. Both, hearing gain and final hearing threshold, however, appear to be independent from the onset of secondary therapy. Based on currently available data from clinical studies, no recommendation can be made with respect to the type of corticosteroid and specifics of the intratympanic application protocol.</p>","PeriodicalId":89377,"journal":{"name":"GMS current topics in otorhinolaryngology, head and neck surgery","volume":"16 ","pages":"Doc05"},"PeriodicalIF":0.0000,"publicationDate":"2018-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5818684/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"GMS current topics in otorhinolaryngology, head and neck surgery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3205/cto000144","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2017/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

This article reviews recent aspects of diagnostics, differential diagnostics, and evidence in systemic and local therapy of idiopathic sudden sensorineural hearing loss (ISSHL). Since a number of disorders can be accompanied by sudden hearing loss, a meaningful and targeted diagnostic strategy is of utmost importance. An important differential diagnosis of sudden hearing loss are intralabyrinthine schwannomas (ILS). The incidence of ILS is probably significantly underestimated. This may be due to the lack of awareness or lack of explicit search for an intralabyrinthine tumor on MRI or an inappropriate MRI technique for the evaluation of sudden hearing loss ("head MRI" instead of "temporal bone MRI" with too high slice thicknesses). Therefore, the request to the radiologist should specifically include the question for (or exclusion of) an ILS. With special MRI techniques, it is possibly today to visualize an endolymphatic hydrops. The evidence in the therapy of ISSHL is - with respect to the quality and not quantity of studies - unsatisfying. The value of systemically (low dose) or intratympanically applied corticosteroids in the primary treatment of ISSHL is still unclear. In order to investigate the efficacy and safety of high dose corticosteroids as primary therapy for ISSHL, a national, multicenter, three-armed, randomized, triple-blind controlled clinical trial is currently performed in Germany (http://hodokort-studie.hno.org/). After insufficient recovery of the threshold with systemic therapy of ISSHL, intratympanic corticosteroid therapy appears to be associated with a significantly higher chance of an improved hearing threshold than no therapy or placebo. Both, hearing gain and final hearing threshold, however, appear to be independent from the onset of secondary therapy. Based on currently available data from clinical studies, no recommendation can be made with respect to the type of corticosteroid and specifics of the intratympanic application protocol.

突发性听力损失的诊断和治疗。
本文回顾了特发性突发性感音神经性听力损失(ISSHL)的诊断、鉴别诊断以及全身和局部治疗证据的最新进展。由于多种疾病都可能伴有突发性听力损失,因此有意义、有针对性的诊断策略至关重要。突发性听力损失的一个重要鉴别诊断是迷宫内分裂瘤(ILS)。ILS 的发病率可能被严重低估。这可能是由于患者缺乏磁共振成像意识或没有明确寻找迷宫内肿瘤,或者在评估突发性听力损失时使用了不恰当的磁共振成像技术("头部磁共振成像 "而不是 "颞骨磁共振成像",切片厚度过高)。因此,在向放射科医生提出申请时,应特别说明是否需要(或排除)ILS。通过特殊的磁共振成像技术,如今有可能看到内淋巴水肿。就研究的质量和数量而言,治疗 ISSHL 的证据并不令人满意。全身(小剂量)或鼓室内应用皮质类固醇在 ISSHL 初级治疗中的价值仍不明确。为了研究大剂量皮质类固醇作为 ISSHL 主要疗法的有效性和安全性,德国目前正在进行一项全国性、多中心、三臂、随机、三盲对照临床试验 (http://hodokort-studie.hno.org/)。在对 ISSHL 进行全身治疗后,听阈仍未得到充分恢复,而采用鼓室内皮质类固醇治疗后,听阈得到改善的几率似乎明显高于不进行治疗或使用安慰剂。不过,听力提高和最终听阈似乎都与二次治疗的开始无关。根据目前现有的临床研究数据,无法就皮质类固醇的类型和鼓室内应用方案的具体细节提出建议。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信